Viking Therapeutics VKTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's stock-based comp?
- Viking Therapeutics (VKTX) reported stock-based comp of $10.34M in Q1 2026.
- How has Viking Therapeutics's stock-based comp changed year-over-year?
- Viking Therapeutics's stock-based comp decreased by 8.9% year-over-year, from $11.35M to $10.34M.
- What is the long-term trend for Viking Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Viking Therapeutics's stock-based comp has grown at a 60.8% compound annual growth rate (CAGR), from $6.1M to $40.82M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.